Uncategorized
Santen releases topline results supporting efficacy, safety of Opsiria for non-infectious uveitis
Topline results for the SAKURA phase 3 program show the efficacy and safety of Opsiria as a potential treatment for non-infectious uveitis of the posterior segment, Santen announced in a press release.Opsiria (440 g sirolimus injection), an intravitreal, locally delivered, targeted immunoregulator, was shown to reduce intraocular inflammation effectively and safely, as measured by vitreous haze, the release said.